We use cookies to understand how you use our site and to improve the overall user experience. This includes personalizing content and advertising. Read our
Privacy Policy
Mycoplasmas are the smallest self-replicating prokaryotes, lacking a cell wall and ranging from 0.2 to 0.8 µm in diameter. Their diminutive size and pleomorphic morphology allow them to penetrate standard 0.1 µm sterilizing-grade filters, making them among the most insidious and difficult-to-eradicate contaminants in mammalian and insect cell culture. Mycoplasma infection does not typically cause turbidity or pH shifts in culture media, rendering visual detection impossible and allowing silent proliferation that alters cell metabolism, gene expression, chromosomal stability, and product quality. Under USP <63>, EP 2.6.7, and ICH Q5D, mycoplasma testing is mandatory for master cell banks (MCB), working cell banks (WCB), viral seed stocks, unprocessed bulk harvests, and certain final drug products. At Profacgen, our Mycoplasma Detection platform delivers comprehensive, compendial-compliant testing—encompassing classical broth-and-agar culture, indicator cell DNA staining, quantitative PCR (qPCR), and validated nucleic acid amplification techniques (NAT)—to ensure your cell substrates and biological products are free from these covert pathogens.
What Challenges Do We Solve?
Mycoplasma contamination is not easy to detect, but it will directly affect the state of cells inadvertently, compromising the integrity of biopharmaceutical development and manufacturing. Profacgen addresses the full spectrum of mycoplasma detection and control challenges:
Covert Infection & Silent Proliferation: Mycoplasmas do not produce visible turbidity, do not cause overt pH changes, and are invisible under standard light microscopy; contaminated cultures can appear morphologically normal while suffering profound metabolic and genetic alterations
Filter Penetration & Aseptic Process Risk: The absence of a peptidoglycan cell wall allows mycoplasmas to deform and pass through 0.1 µm-rated filters, rendering standard sterilizing filtration insufficient and requiring dedicated detection at raw material, cell bank, and bulk harvest stages
Adverse Impact on Cell Physiology: Infection competes for nutrients, induces cytokine dysregulation, alters surface antigen expression, triggers chromosomal aberrations, and suppresses recombinant protein productivity—compromising both research validity and cGMP batch consistency
Prolonged Culture Periods: The compendial gold-standard broth-and-agar culture method requires up to 28 days of incubation, creating critical-path delays for cell banking, batch release, and clinical manufacturing schedules
Method Selection & Regulatory Equivalence: Culture methods, indicator cell assays (DNA fluorochrome staining), and PCR/qPCR each exhibit distinct sensitivity spectra, turnaround times, and regulatory acceptance criteria; selecting and validating the appropriate method for your product stage is essential to avoid deficiency letters
Stringent Regulatory Mandates: Mycoplasma testing is required for MCB/WCB characterization, viral seed stock qualification, unprocessed bulk harvest evaluation, and certain final lot release scenarios under FDA, EMA, and NMPA guidelines
Figure 1. Several methods for detecting mycoplasma contamination. (Weiskirchen et al., 2024)
Our Core Platforms
Profacgen deploys a full suite of compendial and molecular mycoplasma detection platforms. Each method is executed in ISO 5/7 cleanroom environments with validated media, certified reference strains, and rigorous aseptic technique, ensuring data integrity and global regulatory acceptability.
Platform
Capabilities & Deliverables
Culture-Based Mycoplasma Detection
Broth culture (PPLO, SP4, or Hayflick medium) and agar plate inoculation per USP <63> and EP 2.6.7, incubated under aerobic and anaerobic conditions for up to 28 days
Positive control verification using Acholeplasma laidlawii and Mycoplasma orale to demonstrate media growth-promoting properties
Microscopic examination of agar colonies using Dienes staining and sterility confirmation of broth media
Indicator Cell Culture Method (DNA Staining)
Inoculation of test article onto Vero or 3T6 indicator cell monolayers followed by co-culture for a minimum of 3–5 days to amplify low-titer mycoplasmas
Hoechst 33258 or DAPI fluorescent DNA staining to detect extranuclear, punctate or filamentous mycoplasma DNA on indicator cell surfaces
Microscopic examination by epifluorescence microscopy with positive and negative controls, providing orthogonal evidence for non-culturable or fastidious strains
qPCR / Real-Time PCR Detection
Probe-based qPCR targeting conserved 16S rRNA gene sequences or mycoplasma-specific repetitive elements, with sensitivity down to single-genome-equivalent detection
Rapid turnaround (3–5 business days) for cell therapy products, viral seed stocks, and in-process samples where 28-day culture is incompatible with clinical timelines
Extraction efficiency validation and internal amplification controls (IAC) to rule out PCR inhibition from complex biological matrices
Nucleic Acid Amplification Techniques (NAT)
Broad-spectrum NAT assays capable of detecting over 180 mycoplasma species, including M. fermentans, M. hyorhinis, M. arginini, and A. laidlawii—the most common cell culture contaminants
Method equivalence studies comparing NAT to compendial culture methods per FDA and EMA guidance on alternative microbiological methods
Validation packages supporting NAT substitution for routine in-process or release testing after regulatory approval
Comprehensive Cell Bank & Viral Seed Testing
Integrated mycoplasma panels for master cell bank (MCB), working cell bank (WCB), end-of-production cell bank (EOPC), and viral seed stock qualification per ICH Q5D
Parallel execution of culture, indicator cell, and qPCR methods to maximize detection probability and satisfy the most stringent global regulatory dossier requirements
CTD Module 3.2.S.2.3-formatted test reports and certificates of analysis for direct submission
Full Compendial & Molecular Coverage: We offer USP <63> and EP 2.6.7-compliant culture methods, indicator cell DNA staining, qPCR, and broad-spectrum NAT under one quality system, enabling orthogonal confirmation and regulatory flexibility.
Rapid & Classical Methods in Parallel: Our qPCR platform delivers results in 3–5 days for time-critical cell therapies, while concurrent 28-day culture testing provides the compendial gold-standard backup required for cell bank qualification and retrospective verification.
Cell Bank & Viral Seed Specialization: We routinely execute MCB, WCB, EOPC, and viral seed stock mycoplasma panels with CTD-formatted reports designed for direct inclusion in IND, BLA, and MAA submissions.
Matrix-Optimized Extraction: Proprietary lysis and DNA extraction protocols overcome PCR inhibition from serum, cellular debris, lipid nanoparticles, and high-protein formulations, ensuring reliable molecular detection in complex biologic matrices.
Regulatory-Ready Documentation: Method suitability reports, validation protocols, equivalence studies, and contamination investigation narratives are prepared to withstand FDA, EMA, and NMPA scrutiny.
Contamination Investigation & Root Cause: When positives occur, our species-level identification and forensic analysis capabilities enable rapid tracing to raw materials, equipment, or environmental sources, with full CAPA documentation.
Application Scenarios
Scenario 1: Master & Working Cell Bank Qualification
Challenge:
A biopharmaceutical company preparing an IND for a novel monoclonal antibody required comprehensive MCB and WCB characterization. Regulatory guidelines mandated mycoplasma testing as a prerequisite for cell bank acceptance, and the client needed a defensible, multi-method package to satisfy the reviewers of regulatory agencies.
Our Approach:
We executed the full ICH Q5D mycoplasma panel: broth-and-agar culture incubated for 28 days under aerobic and anaerobic conditions with A. laidlawii and M. orale positive controls; parallel indicator cell culture on Vero cells with Hoechst 33258 staining; and confirmatory qPCR targeting the 16S rRNA conserved region. All three methods returned negative, and the extraction efficiency control confirmed no PCR inhibition from the cell bank matrix.
Outcome:
The integrated mycoplasma clearance data were included in the CTD Module 3.2.S.2.3 cell substrate section. Regulatory agencies accepted the package without requesting additional testing, enabling the client to proceed directly to Phase I clinical manufacturing using the qualified banks.
Scenario 2: Autologous Cell Therapy Rapid Release
Challenge:
An autologous CAR-T therapy developer faced a stringent timeline constraint: patient-derived cells were expanded over 14 days, and the final product had a 48-hour window from harvest to infusion. The 28-day compendial culture method was incompatible with clinical administration, yet timely evidence of mycoplasma clearance was required prior to product release.
Our Approach:
We validated a probe-based qPCR assay targeting a broad-spectrum mycoplasma 16S rRNA consensus sequence, achieving a detection limit of 10 genome copies per reaction with high specificity against human DNA and common bacterial contaminants. The method was cross-validated against the 28-day culture reference using 60 spiked cell therapy matrices. In parallel, the compendial culture test was initiated to provide retrospective confirmation.
Outcome:
The validated qPCR method was accepted as a rapid testing strategy for prospective lot release, with the 28-day culture assay serving as a complementary retrospective safeguard. The client successfully released multiple clinical batches on schedule, and no mycoplasma contamination was detected in any concurrent culture test, demonstrating the reliability of the rapid method.
Q: What are mycoplasmas and why are they critical contaminants in cell culture?
A: Mycoplasmas are the smallest self-replicating bacteria, lacking a cell wall and ranging from 0.2 to 0.8 µm. They are critical contaminants because they can penetrate 0.1 µm filters, do not produce visible turbidity or pH changes, and are invisible under standard microscopy. Despite their covert presence, they alter cell metabolism, suppress productivity, induce chromosomal abnormalities, and compromise the safety and quality of biological products.
Q: Which regulatory guidelines require mycoplasma testing?
A: USP <63> (Mycoplasma Tests), EP 2.6.7 (Mycoplasmas), and ICH Q5D (Derivation and Characterization of Cell Substrates) mandate mycoplasma testing for master cell banks, working cell banks, and viral seed stocks. FDA and EMA guidance further require testing for unprocessed bulk harvests and certain final products, particularly live and attenuated biologicals.
Q: What are the differences between culture-based and PCR-based mycoplasma detection?
A: Culture-based methods (broth and agar) are the compendial gold standard, capable of detecting viable mycoplasmas but requiring up to 28 days. PCR/qPCR detects mycoplasma DNA with high sensitivity and specificity in 3–5 days, making it ideal for rapid release. However, PCR cannot distinguish viable from non-viable organisms and may be subject to matrix inhibition. Regulators often require culture for cell bank qualification while accepting validated PCR for in-process or product release.
Q: How long does traditional mycoplasma culture testing take?
A: USP <63> and EP 2.6.7 require broth cultures to be incubated for a minimum of 21 days and agar cultures for 14 days, with many laboratories extending broth incubation to 28 days to maximize detection of slow-growing strains. This prolonged timeline is a major bottleneck for cell banking and batch release, which is why orthogonal rapid methods are increasingly employed for time-critical applications.
Q: Can qPCR or NAT replace compendial culture methods for mycoplasma testing?
A: For cell bank and viral seed stock qualification, most regulators still require the 28-day culture method as the primary standard. For in-process testing, bulk harvest evaluation, and rapid product release, validated qPCR or NAT can substitute after demonstrating equivalence to the compendial reference through parallel testing and method validation. Profacgen provides full equivalence study packages to support regulatory approval of rapid methods.
Q: At which stages of biopharmaceutical production is mycoplasma testing required?
A: Mycoplasma testing is required for master cell banks (MCB), working cell banks (WCB), end-of-production cells (EOPC), viral seed stocks, and unprocessed bulk harvests. For certain live or attenuated products, regulators may also require testing of the final drug product. Testing should also be performed on raw materials of biological origin—particularly serum and trypsin—that are common sources of introduction.
Q: What is the indicator cell culture method and when is it used?
A: The indicator cell method involves inoculating the test article onto a susceptible monolayer (e.g., Vero or 3T6 cells), co-culturing for several days to amplify low-titer mycoplasmas, and then staining with Hoechst 33258 or DAPI to visualize extranuclear mycoplasma DNA by fluorescence microscopy. It is used as an orthogonal technique to culture methods, particularly for detecting fastidious or non-culturable strains, and is required by USP <63> and EP 2.6.7 for cell bank qualification.
References:
Weiskirchen S, Monteiro AM, Borojevic R, Weiskirchen R. Unlocking potential: a comprehensive overview of cell culture banks and their impact on biomedical research. Cells. 2024;13(22):1861. doi:10.3390/cells13221861
Online Inquiry
Fill out this form and one of our experts will respond to you within one business day.
Figure 1. Several methods for detecting mycoplasma contamination. (Weiskirchen et al., 2024)